The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer; Pfizer; Pfizer; Pfizer
Speakers' Bureau - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; EUSA Pharma; EUSA Pharma; EUSA Pharma; EUSA Pharma
HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).
 
Margaret A. Tempero
Honoraria - Japan Pancreas Society; Japan Pancreas Society; Japan Pancreas Society; Japan Pancreas Society; Oregon Health & Science University (OHSU); Oregon Health & Science University (OHSU); Oregon Health & Science University (OHSU); Oregon Health & Science University (OHSU)
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Advance Medical; Advance Medical; Advance Medical; Advance Medical; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BIOPHARM; BIOPHARM; BIOPHARM; BIOPHARM; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); CPRIT; CPRIT; CPRIT; CPRIT; EcoR1 Capital; EcoR1 Capital; EcoR1 Capital; EcoR1 Capital; Eisai; Eisai; Eisai; Eisai; FibroGen (Inst); FibroGen (Inst); FibroGen (Inst); FibroGen (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Ignyta; Ignyta; Ignyta; Ignyta; Immunovia; Immunovia; Immunovia; Immunovia; Merck; Merck; Merck; Merck; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Tocagen; Tocagen; Tocagen; Tocagen
Research Funding - Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst)
Travel, Accommodations, Expenses - Abbvie; Abbvie; Abbvie; Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BIOPHARM; BIOPHARM; BIOPHARM; BIOPHARM; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; CPRIT; CPRIT; CPRIT; CPRIT; Eisai; Eisai; Eisai; Eisai; Halozyme; Halozyme; Halozyme; Halozyme; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Tocagen; Tocagen; Tocagen; Tocagen
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Lilly; Lilly; Lilly; Lilly; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - amgen (Inst); amgen (Inst); amgen (Inst); amgen (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst)
 
Darren Sigal
Stock and Other Ownership Interests - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Halozyme; Halozyme; Halozyme; Halozyme; Novartis; Novartis; Novartis; Novartis
Speakers' Bureau - Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene
Research Funding - Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst)
 
Do-Youn Oh
Research Funding - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
 
Nicola Fazio
Honoraria - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Sanofi; Sanofi; Sanofi; Sanofi
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Ipsen; Ipsen; Ipsen; Ipsen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis/Ipsen; Novartis/Ipsen; Novartis/Ipsen; Novartis/Ipsen; Pfizer; Pfizer; Pfizer; Pfizer; Wren Laboratories; Wren Laboratories; Wren Laboratories; Wren Laboratories
Research Funding - Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst)
Other Relationship - Il Pensiero Scientifico Editore; Il Pensiero Scientifico Editore; Il Pensiero Scientifico Editore; Il Pensiero Scientifico Editore; Springer; Springer; Springer; Springer
 
Teresa Macarulla
No Relationships to Disclose
 
Erika Hitre
No Relationships to Disclose
 
Pascal Hammel
Honoraria - Celgene; Celgene; Celgene; Celgene
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Celgene; Celgene; Celgene; Celgene; ERYTECH Pharma (Inst); ERYTECH Pharma (Inst); ERYTECH Pharma (Inst); ERYTECH Pharma (Inst); Halozyme; Halozyme; Halozyme; Halozyme; Shire; Shire; Shire; Shire; VECT-HORUS; VECT-HORUS; VECT-HORUS; VECT-HORUS
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Shire; Shire; Shire; Shire
Travel, Accommodations, Expenses - Halozyme; Halozyme; Halozyme; Halozyme; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Shire; Shire; Shire; Shire
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Celgene; Celgene; Celgene; Celgene; Ipsen; Ipsen; Ipsen; Ipsen; Novartis; Novartis; Novartis; Novartis; Perthera; Perthera; Perthera; Perthera
Research Funding - Ipsen; Ipsen; Ipsen; Ipsen
Travel, Accommodations, Expenses - Halozyme; Halozyme; Halozyme; Halozyme
 
Susan Elaine Bates
Research Funding - Agios; Agios; Agios; Agios
Patents, Royalties, Other Intellectual Property - Patent: Deacetylase Inhibitor Therapy (Inst); Patent: Deacetylase Inhibitor Therapy (Inst); Patent: Deacetylase Inhibitor Therapy (Inst); Patent: Deacetylase Inhibitor Therapy (Inst); Patent: Depsipeptide for Therapy of Kidney Cancer (Inst); Patent: Depsipeptide for Therapy of Kidney Cancer (Inst); Patent: Depsipeptide for Therapy of Kidney Cancer (Inst); Patent: Depsipeptide for Therapy of Kidney Cancer (Inst)
 
Chung-Pin Li
No Relationships to Disclose
 
Christelle De La Fouchardiere
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER; Shire; Shire; Shire; Shire
Research Funding - Roche; Roche; Roche; Roche
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
 
Volker Heinemann
Honoraria - Amgen; Amgen; Amgen; Amgen; Baxalta; Baxalta; Baxalta; Baxalta; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Baxalta; Baxalta; Baxalta; Baxalta; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Servier (Inst); Servier (Inst); Servier (Inst); Servier (Inst); Shire (Inst); Shire (Inst); Shire (Inst); Shire (Inst); Sirtex Medical (Inst); Sirtex Medical (Inst); Sirtex Medical (Inst); Sirtex Medical (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER; Shire; Shire; Shire; Shire; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
 
Anthony Maraveyas
No Relationships to Disclose
 
Nathan Bahary
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Exelixis; Exelixis; Exelixis; Exelixis; Thermo Fisher Scientific; Thermo Fisher Scientific; Thermo Fisher Scientific; Thermo Fisher Scientific
 
Laura Layos
No Relationships to Disclose
 
Vaibhav Sahai
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Klus Pharma; Klus Pharma; Klus Pharma; Klus Pharma; Newlink Genetics; Newlink Genetics; Newlink Genetics; Newlink Genetics; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics
Research Funding - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); FibroGen (Inst); FibroGen (Inst); FibroGen (Inst); FibroGen (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Rafael Pharmaceuticals (Inst); Rafael Pharmaceuticals (Inst); Rafael Pharmaceuticals (Inst); Rafael Pharmaceuticals (Inst)
 
Lei Zheng
Stock and Other Ownership Interests - Z and L International Medical; Z and L International Medical; Z and L International Medical; Z and L International Medical
Consulting or Advisory Role - Alphamab; Alphamab; Alphamab; Alphamab; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Biosynergies; Biosynergies; Biosynergies; Biosynergies; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Merck; Merck; Merck; Merck; Merrimack; Merrimack; Merrimack; Merrimack; Mingruizhiyao; Mingruizhiyao; Mingruizhiyao; Mingruizhiyao; novarock; novarock; novarock; novarock
Research Funding - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gradalis; Gradalis; Gradalis; Gradalis; Halozyme; Halozyme; Halozyme; Halozyme; InxMed; InxMed; InxMed; InxMed; ITeos Therapeutics; ITeos Therapeutics; ITeos Therapeutics; ITeos Therapeutics; Merck; Merck; Merck; Merck; NovaRock; NovaRock; NovaRock; NovaRock
Patents, Royalties, Other Intellectual Property - GVAX, licensed to Aduro Biotech.; GVAX, licensed to Aduro Biotech.; GVAX, licensed to Aduro Biotech.; GVAX, licensed to Aduro Biotech.
 
Jill Lacy
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Celgene; Celgene; Celgene; Celgene; KeyQuest Health; KeyQuest Health; KeyQuest Health; KeyQuest Health; Merck; Merck; Merck; Merck; Navigant Consulting; Navigant Consulting; Navigant Consulting; Navigant Consulting; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Travel, Accommodations, Expenses - Lilly; Lilly; Lilly; Lilly
 
Andrea J. Bullock
Stock and Other Ownership Interests - Amgen; Amgen; Amgen; Amgen; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Medtronic; Medtronic; Medtronic; Medtronic
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Halozyme; Halozyme; Halozyme; Halozyme